| (Values in U.S. Thousands) | Jun, 2024 | Mar, 2024 | Dec, 2023 | Sep, 2023 | Jun, 2023 |
| Sales | 590 | 540 | 710 | 460 | 520 |
| Sales Growth | +9.26% | -23.94% | +54.35% | -11.54% | -27.78% |
| Net Income | -7,070 | -7,740 | -8,490 | -10,150 | -11,100 |
| Net Income Growth | +8.66% | +8.83% | +16.35% | +8.56% | +8.34% |
Renalytix Ai Plc ADR (RNLX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Renalytix AI plc is an artificial intelligence-enabled in vitro diagnostics company. It focuses on optimizing clinical management of kidney disease. Renalytix AI plc is based in NEW YORK.